A resolution expressing the sense of the Senate that the scientific judgement of the Food and Drug Administration that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable and based on science.

This Senate resolution (SRES 510) expresses the Senate's support for respecting the FDA's scientific determination that mifepristone - a medication used for early pregnancy termination - is safe and effective. It calls for abortion care policies to be "equitable and based on science," emphasizing the FDA's authority to regulate the drug without interference, including its 2023 update allowing mail-order access. The resolution directly addresses the impact of state restrictions on medication abortion, noting that such policies disproportionately affect Black and Indigenous people, people of color, low-income individuals, rural communities, and other marginalized groups. As a non-binding resolution, it does not change laws but urges alignment with FDA science to protect access to this time-sensitive care.